Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540078 | 1.00 | GUSB (0.61) | GUSBMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL21399787 | 0.90 | GUSB (0.52) | GUSBMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL3343111 | 0.85 | MAPT (0.69) | MAPTMEN1KMT2ANPSR1TDP1 | |
| SCHEMBL30040360 | 0.85 | MAPT (0.69) | MAPTMEN1KMT2ANPSR1TDP1 | |
| SCHEMBL24145351 | 0.83 | GUSB (0.69) | GUSBMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL3344603 | 0.83 | NR3C1 (0.61) | MAPTMEN1KMT2ANPSR1TDP1 | |
| SCHEMBL3493350 | 0.83 | GUSB (0.58) | GUSBMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL31511311 | 0.83 | NR3C1 (0.57) | GUSBMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL24145185 | 0.83 | NR3C1 (0.57) | GUSBMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL3493768 | 0.83 | NR3C1 (0.61) | GUSBMAPTMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188169-A1 | METHOD FOR TREATING CLONAL HEMATOPOIETIC BLOOD DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-12 | — | — | US | claimed |
| US-20220265606-A1 | ANTICANCER AGENTS | THE TEXAS A&M UNIVERSITY SYSTEM | 2022-08-25 | — | — | US | claimed |
| CN-113533786-A | Method for researching anti-pollution action mechanism of diindole alkaloid on Nitzschia closterium based on electron microscopic imaging technology | 大理大学 | 2021-10-22 | — | — | CN | claimed |
| US-20160303081-A1 | INHIBITORS OF BETA1-INTEGRIN AND METHODS OF USE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2016-10-20 | — | — | US | claimed |
| US-20100087504-A1 | Use of Diindolylmethane (DIM) Compounds and Derivatives as Neuroprotective Agents | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-04-08 | — | — | US | claimed |
| US-12622892-B2 | Methods for treating endometriosis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12410220-B2 | Modulation of mammalian cell lineage by synthetic immodulins | MASCARENHAS DESMOND (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4110056-B1 | NR4A1 MODULATORS FOR USE IN THE TREATMENT OF ENDOMETRIOSIS | TEXAS A & M UNIV SYS (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250188169-A1 | METHOD FOR TREATING CLONAL HEMATOPOIETIC BLOOD DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-20240327480-A1 | MODULATION OF MAMMALIAN CELL LINEAGE BY SYNTHETIC IMMODULINS | MASCARENHAS DESMOND (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240034761-A1 | REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS | MASCARENHAS DESMOND (US) | 2024-02-01 | — | — | US | disclosed |
| WO-2023192969-A1 | METHOD FOR TREATING CLONAL HEMATOPOIETIC BLOOD DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-8580843-B2 | Use of diindolylmethane (DIM) compounds and derivatives as neuroprotective agents | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580843-B2 | Use of diindolylmethane (DIM) compounds and derivatives as neuroprotective agents | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580843-B2 | Use of diindolylmethane (DIM) compounds and derivatives as neuroprotective agents | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2010042657-A1 | USE OF DIINDOLYLMETHANE (DIM) COMPOUNDS AND DERIVATIVES AS NEUROPROTECTIVE AGENTS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100087504-A1 | Use of Diindolylmethane (DIM) Compounds and Derivatives as Neuroprotective Agents | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087504-A1 | Use of Diindolylmethane (DIM) Compounds and Derivatives as Neuroprotective Agents | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087504-A1 | Use of Diindolylmethane (DIM) Compounds and Derivatives as Neuroprotective Agents | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265606-A1 | ANTICANCER AGENTS | NR4A2, NR4A3, NR4A1 | GUSB 3056/4885MAPT 3667/4885MEN1 3695/4885 |
| US-12622892-B2 | Methods for treating endometriosis | NR4A1, NR4A3, NR0B1 | GUSB 2485/4885MAPT 4851/4885MEN1 4773/4885 |
| US-20100087504-A1 | Use of Diindolylmethane (DIM) Compounds and Derivatives as Neuroprotective Agents | AIFM1, NLN, SNCA | GUSB 4532/4885MAPT 123/4885MEN1 4042/4885 |
| US-20160303081-A1 | INHIBITORS OF BETA1-INTEGRIN AND METHODS OF USE | ITGB3, ITGB1, ITGB4 | GUSB 1732/4885MAPT 4590/4885MEN1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.